FIREFLY NEUROSCIENCE, INC. 10-K — AI Bull & Bear Analysis

The 10-K filing paints a picture of a company at a binary inflection point. On one hand, the Evoke acquisition has provided Firefly with the technical and data assets necessary to dominate the point-of-care EEG market. The shift toward a subscription-based model and the ability to partner with pharmaceutical giants like Novartis for biomarker validation provide a credible path toward high-margin scalability. However, these operational wins are currently overshadowed by a precarious balance sheet. The tension between the 'data moat' thesis and the 'cash burn' reality creates a high-risk profile for investors. The ultimate outcome depends on whether the company can secure enough bridge capital to survive its current burn rate long enough for the subscription revenue to reach a critical mass. Investors are essentially betting on the speed of commercial adoption versus the speed of cash depletion.